Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment

Mederacke I., Yurdaydin C., Dalekos G. N., Bremer B., Erhardt A., Cakaloglu Y., ...Daha Fazla

ANTIVIRAL THERAPY, cilt.17, sa.2, ss.305-312, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.3851/imp1926
  • Dergi Adı: ANTIVIRAL THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.305-312
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone.